FIELD: bioengineering.
SUBSTANCE: analogue of exenatide with formula H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Gly-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Gly-OH is suggested.
EFFECT: invention ensures medical treatment and preventive treatment of the pancreatic diabetes, as well as medical treatment and preventive treatment of complications of the pancreatic diabetes of 2nd type, such as diabetic neuropathy, muscular dystrophy and endotheliopathy.
3 dwg, 7 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANALGESIC AGENT OF PEPTIDE STRUCTURE BASED ON TRIDECAPEPTIDE CONTAINING D-OCTAARGININE VECTOR | 2013 |
|
RU2538727C1 |
| METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
| AGENT OF PEPTIDE STRUCTURE, INHIBITING DIPEPTIDYL PEPTIDASE-4, AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2015 |
|
RU2589258C1 |
| ANALGESIC AGENT OF PEPTIDE STRUCTURE OF UNDERCAPEPTIDE CONTAINING D-OCTAARGININE VECTOR | 2013 |
|
RU2541127C1 |
| HYPOGLYCEMIC AGENT OF PEPTIDE STRUCTURE INHIBITING DIPEPTIDYL PEPTIDASE-4 | 2015 |
|
RU2600810C1 |
| EXENATIDE ANALOGUE | 2020 |
|
RU2823623C1 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
| SYNTHESIS OF LIXISENATIDE WITH CAPPING | 2019 |
|
RU2782772C2 |
| METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | 2019 |
|
RU2771712C2 |
